Skip to main content

Table 8 Selected studies for myeloproliferative neoplasm from 2020 ASH annual meeting

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Abstract # Authors (references) Study agents Phase NCT No
3442 Kish et al. [74] Ruxolitinib Retrospective N/A
2518 Passamonti et.al. [75] Ruxolitinib Retrospective N/A
1250 Drummond et.al. [77] Vidaza/Ruxolitinib 1b ISRCTN 16783472
54 Verstovsek et al. [82] Momelotinib Extension Study N/A
3002 Potluri et.al. [87] Navitoclax/Rux III NCT04472598
1255 Dilley et al. [86] Navitoclax/Rux III NCT04468984
52 Pemmaraju et al. [88] Navitoclax/Rux II N/A
483 Daltro De Oliveira et al. [90] Interferon-Alpha N/A N/A